Britta Besemer

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications

Title Not Found

Title Not Found

Journal: Deutsche medizinische Wochenschrift (1946)
Published: August 10, 2026

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 21, 2026

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022.

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022.

Journal: British journal of haematology
Published: May 15, 2026

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Journal: The New England journal of medicine
Published: December 09, 2025

Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.

Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.

Journal: Haematologica
Published: October 26, 2025

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Journal: Leukemia & lymphoma
Published: October 03, 2025

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Journal: Advances in therapy
Published: September 02, 2025

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.

Journal: Blood advances
Published: July 15, 2025

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

Journal: European journal of haematology
Published: July 07, 2025

Prospective systematic classification of causes of death in the course of multiple myeloma.

Prospective systematic classification of causes of death in the course of multiple myeloma.

Journal: Blood cancer journal
Published: July 02, 2025

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Journal: Blood
Published: June 04, 2025
Showing 1-12 of 58

Last Updated: 09/26/2026